[1]

Tan TE, Wong TY. 2023. Diabetic retinopathy: looking forward to 2030. Frontiers in Endocrinology 13:1077669

doi: 10.3389/fendo.2022.1077669
[2]

Tomkins-Netzer O, Niederer R, Lightman S. 2024. The role of statins in diabetic retinopathy. Trends in Cardiovascular Medicine 34(2):128−135

doi: 10.1016/j.tcm.2022.11.003
[3]

Pan Z, Zhao Y, Zhou S, Wang J, Fan F. 2023. CD44 drives M1 macrophage polarization in diabetic retinopathy. Current Eye Research 48(8):770−780

doi: 10.1080/02713683.2023.2210273
[4]

He S, Gu C, Su T, Qiu Q. 2022. Research progress of circRNAs in inflammatory mechanisms of diabetic retinopathy: an emerging star with potential therapeutic targets. Current Eye Research 47(2):165−178

doi: 10.1080/02713683.2021.1995002
[5]

Andrés-Blasco I, Gallego-Martínez A, Machado X, Cruz-Espinosa J, Di Lauro S, et al. 2023. Oxidative stress, inflammatory, angiogenic, and apoptotic molecules in proliferative diabetic retinopathy and diabetic macular edema patients. International Journal of Molecular Sciences 24(9):8227

doi: 10.3390/ijms24098227
[6]

Chen YT, Radke NV, Amarasekera S, Park DH, Chen N, et al. 2025. Updates on medical and surgical managements of diabetic retinopathy and maculopathy. Asia-Pacific Journal of Ophthalmology 14(2):100180

doi: 10.1016/j.apjo.2025.100180
[7]

Lai D, Wu Y, Shao C, Qiu Q. 2023. The role of Müller cells in diabetic macular edema. Investigative Opthalmology & Visual Science 64(10):8

doi: 10.1167/iovs.64.10.8
[8]

Kumari N, Barman S, Ganesan SK. 2025. Crosstalk between neuronal and glial cells in diabetic retinopathy: mechanisms and implications for neurodegeneration. Molecular Neurobiology 63(1):173

doi: 10.1007/s12035-025-05546-5
[9]

Li Y, Zhu L, Cai MX, Wang ZL, Zhuang M, et al. 2023. TGR5 supresses cGAS/STING pathway by inhibiting GRP75-mediated endoplasmic reticulum-mitochondrial coupling in diabetic retinopathy. Cell Death & Disease 14(9):583

doi: 10.1038/s41419-023-06111-5
[10]

Li Q, Cheng Y, Zhang S, Sun X, Wu J. 2021. TRPV4-induced Müller cell gliosis and TNF-α elevation-mediated retinal ganglion cell apoptosis in glaucomatous rats via JAK2/STAT3/NF-κB pathway. Journal of Neuroinflammation 18(1):271

doi: 10.1186/s12974-021-02315-8
[11]

Zwanzig A, Meng J, Müller H, Bürger S, Schmidt M, et al. 2021. Neuroprotective effects of glial mediators in interactions between retinal neurons and Müller cells. Experimental Eye Research 209:108689

doi: 10.1016/j.exer.2021.108689
[12]

Inada M, Xu H, Takeuchi M, Ito M, Chen M. 2021. Microglia increase tight-junction permeability in coordination with Müller cells under hypoxic condition in an in vitro model of inner blood-retinal barrier. Experimental Eye Research 205:108490

doi: 10.1016/j.exer.2021.108490
[13]

Rolev KD, Shu XS, Ying Y. 2021. Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy. Neuropharmacology 187:108498

doi: 10.1016/j.neuropharm.2021.108498
[14]

Zhang Y, Xu N, Ding Y, Zhang Y, Li Q, et al. 2018. Chemerin suppresses neuroinflammation and improves neurological recovery via CaMKK2/AMPK/Nrf2 pathway after germinal matrix hemorrhage in neonatal rats. Brain, Behavior, and Immunity 70:179−193

doi: 10.1016/j.bbi.2018.02.015
[15]

Zhang Y, Xu N, Ding Y, Doycheva DM, Zhang Y, et al. 2019. RETRACTED ARTICLE: chemerin reverses neurological impairments and ameliorates neuronal apoptosis through ChemR23/CAMKK2/AMPK pathway in neonatal hypoxic-ischemic encephalopathy. Cell Death & Disease 10(2):97

doi: 10.1038/s41419-019-1374-y
[16]

Zhang H, Lin A, Gong P, Chen Y, Ye RD, et al. 2020. The chemokine-like receptor 1 deficiency improves cognitive deficits of AD mice and attenuates tau hyperphosphorylation via regulating tau seeding. The Journal of Neuroscience 40(36):6991−7007

doi: 10.1523/jneurosci.0455-20.2020
[17]

Corrêa GF, Martins NS, Cipriano UG, Gembre AF, Rodrigues D, et al. 2025. Chemerin exacerbates pulmonary inflammation in type 2 diabetes and Mycobacterium Tuberculosis infection comorbidity. Inflammation 48(6):4517−4532

doi: 10.1007/s10753-025-02343-z
[18]

Li J, Song L, Song H. 2021. Chemerin promotes microangiopathy in diabetic retinopathy via activation of ChemR23 in rat primary microvascular endothelial cells. Molecular Vision 27:575−587
[19]

Bäck M. 2023. Icosapent ethyl in cardiovascular prevention: resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis. Pharmacology & Therapeutics 247:108439

doi: 10.1016/j.pharmthera.2023.108439
[20]

Su X, Cheng Y, Zhang G, Wang B. 2021. Chemerin in inflammatory diseases. Clinica Chimica Acta 517:41−47

doi: 10.1016/j.cca.2021.02.010
[21]

Zhang J, Yin Z, Xu Y, Wei C, Peng S, et al. 2023. Resolvin E1/ChemR23 protects against hypertension and vascular remodeling in angiotensin II-induced hypertensive mice. Hypertension 80(12):2650−2664

doi: 10.1161/HYPERTENSIONAHA.123.21348
[22]

Salas-Hernández A, Espinoza-Pérez C, Vivar R, Espitia-Corredor J, Lillo J, et al. 2021. Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro. Molecular Biology Reports 48(1):57−66

doi: 10.1007/s11033-020-06133-8
[23]

Xie Y, Liu L. 2022. Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction. Journal of Translational Medicine 20(1):141

doi: 10.1186/s12967-021-03220-7
[24]

Liu L, Zhang J, Lu K, Zhang Y, Xu X, et al. 2024. ChemR23 signaling ameliorates brain injury via inhibiting NLRP3 inflammasome-mediated neuronal pyroptosis in ischemic stroke. Journal of Translational Medicine 22(1):23

doi: 10.1186/s12967-023-04813-0
[25]

Suzuki H, Otsuka T, Hitora-Imamura N, Ishimura K, Fukuda H, et al. 2021. Resolvin E1 attenuates chronic pain-induced depression-like behavior in mice: possible involvement of chemerin receptor ChemR23. Biological and Pharmaceutical Bulletin 44(10):1548−1550

doi: 10.1248/bpb.b21-00461
[26]

Zhang Y, Zhang J, Zhao Y, Zhang Y, Liu L, et al. 2023. ChemR23 activation attenuates cognitive impairment in chronic cerebral hypoperfusion by inhibiting NLRP3 inflammasome-induced neuronal pyroptosis. Cell Death & Disease 14(11):721

doi: 10.1038/s41419-023-06237-6
[27]

Grewal AK, Singh N, Singh TG. 2019. Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia–reperfusion-induced injury in mice. Journal of Pharmacy and Pharmacology 71(6):956−970

doi: 10.1111/jphp.13073
[28]

Laffranchi M, Schioppa T, Sozio F, Piserà A, Tiberio L, et al. 2025. Chemerin in immunity. Journal of Leukocyte Biology 117(3):qiae181

doi: 10.1093/jleuko/qiae181
[29]

Jin Z, Li G, He D, Chen J, Zhang Y, et al. 2025. An overview of small-molecule agents for the treatment of psoriasis. Bioorganic & Medicinal Chemistry 119:118067

doi: 10.1016/j.bmc.2025.118067
[30]

Shang J, Wang L, Zhang Y, Zhang S, Ning L, et al. 2019. Chemerin/ChemR23 axis promotes inflammation of glomerular endothelial cells in diabetic nephropathy. Journal of Cellular and Molecular Medicine 23(5):3417−3428

doi: 10.1111/jcmm.14237
[31]

Zhang X, Weiß T, Cheng MH, Chen S, Ambrosius CK, et al. 2023. Structural basis of CMKLR1 signaling induced by chemerin9. bioRxiv 544295

doi: 10.1101/2023.06.09.544295
[32]

Zhang J, Liu L, Zhang Y, Yuan Y, Miao Z, et al. 2022. ChemR23 signaling ameliorates cognitive impairments in diabetic mice via dampening oxidative stress and NLRP3 inflammasome activation. Redox Biology 58:102554

doi: 10.1016/j.redox.2022.102554
[33]

Yang Q, Lin X, Xiao J, Zhong W, Wang F, et al. 2023. Expression of α-Synuclein in the mouse retina is confined to inhibitory presynaptic elements. Journal of Comparative Neurology 531(10):1057−1079

doi: 10.1002/cne.25481
[34]

Rangasamy S, Monickaraj F, Legendre C, Cabrera AP, Llaci L, et al. 2020. Transcriptomics analysis of pericytes from retinas of diabetic animals reveals novel genes and molecular pathways relevant to blood-retinal barrier alterations in diabetic retinopathy. Experimental Eye Research 195:108043

doi: 10.1016/j.exer.2020.108043
[35]

Ramos H, Bogdanov P, Sabater D, Huerta J, Valeri M, et al. 2021. Neuromodulation induced by sitagliptin: a new strategy for treating diabetic retinopathy. Biomedicines 9(12):1772

doi: 10.3390/biomedicines9121772
[36]

Orhan C, Tuzcu M, Gencoglu H, Sahin E, Sahin N, et al. 2021. Different doses of β-cryptoxanthin may secure the retina from photooxidative injury resulted from common LED sources. Oxidative Medicine and Cellular Longevity 2021:6672525

doi: 10.1155/2021/6672525
[37]

Mohammad HMF, Sami MM, Makary S, Toraih EA, Mohamed AO, et al. 2019. Neuroprotective effect of levetiracetam in mouse diabetic retinopathy: effect on glucose transporter-1 and GAP43 expression. Life Sciences 232:116588

doi: 10.1016/j.lfs.2019.116588
[38]

Sanchez MC, Chiabrando GA. 2022. Multitarget activities of Müller glial cells and low-density lipoprotein receptor-related protein 1 in proliferative retinopathies. ASN Neuro 14:17590914221136365

doi: 10.1177/17590914221136365
[39]

Carpi-Santos R, de Melo Reis RA, Gomes FCA, Calaza KC. 2022. Contribution of Müller cells in the diabetic retinopathy development: focus on oxidative stress and inflammation. Antioxidants 11(4):617

doi: 10.3390/antiox11040617
[40]

Du X, Yang L, Kong L, Sun Y, Shen K, et al. 2022. Metabolomics of various samples advancing biomarker discovery and pathogenesis elucidation for diabetic retinopathy. Frontiers in Endocrinology 13:1037164

doi: 10.3389/fendo.2022.1037164
[41]

Lu Z, Fan B, Li Y, Zhang Y. 2023. RAGE plays key role in diabetic retinopathy: a review. BioMedical Engineering OnLine 22(1):128

doi: 10.1186/s12938-023-01194-9
[42]

Li JJ, Yin HK, Guan DX, Zhao JS, Feng YX, et al. 2018. Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. British Journal of Cancer 118(10):1337−1348

doi: 10.1038/s41416-018-0077-y
[43]

Rennier K, Shin WJ, Krug E, Virdi G, Pachynski RK. 2020. Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via modulation of a novel CMKLR1-mediated signaling cascade. Clinical Cancer Research 26(18):5019−5035

doi: 10.1158/1078-0432.CCR-19-4245
[44]

Ben Dhaou C, Mandi K, Frye M, Acheampong A, Radi A, et al. 2022. Chemerin regulates normal angiogenesis and hypoxia-driven neovascularization. Angiogenesis 25(2):159−179

doi: 10.1007/s10456-021-09818-1
[45]

Jing Y, Zhang Y, Wang X, Wang Y, Hu Y, et al. 2025. MBD2 promotes B cell differentiation and BCR signaling in systemic lupus erythematosus by regulating the LEF-1-PTEN-PI3K axis. Cell Death & Disease 16(1):433

doi: 10.1038/s41419-025-07750-6
[46]

Liu BH, Tu Y, Ni GX, Yan J, Yue L, et al. 2021. Total flavones of Abelmoschus manihot ameliorates podocyte pyroptosis and injury in high glucose conditions by targeting METTL3-dependent m6A modification-mediated NLRP3-inflammasome activation and PTEN/PI3K/Akt signaling. Frontiers in Pharmacology 12:667644

doi: 10.3389/fphar.2021.667644
[47]

Li J, Chen K, Li X, Zhang X, Zhang L, et al. 2023. Mechanistic insights into the alterations and regulation of the AKT signaling pathway in diabetic retinopathy. Cell Death Discovery 9(1):418

doi: 10.1038/s41420-023-01717-2